- Home
- STAA vs SPRY Comparison
STAA vs SPRY Comparison
Compare STAA & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAA
- SPRY
- Stock Information
- Founded
- STAA 1982
- SPRY 2015
- Country
- STAA United States
- SPRY United States
- Employees
- STAA N/A
- SPRY N/A
- Industry
- STAA Ophthalmic Goods
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- STAA Health Care
- SPRY Health Care
- Exchange
- STAA Nasdaq
- SPRY Nasdaq
- Market Cap
- STAA 1.2B
- SPRY 1.1B
- IPO Year
- STAA N/A
- SPRY N/A
- Fundamental
- Price
- STAA $23.52
- SPRY $12.95
- Analyst Decision
- STAA Buy
- SPRY Strong Buy
- Analyst Count
- STAA 7
- SPRY 4
- Target Price
- STAA $42.83
- SPRY $26.00
- AVG Volume (30 Days)
- STAA 701.0K
- SPRY 1.4M
- Earning Date
- STAA 02-19-2025
- SPRY 03-20-2025
- Dividend Yield
- STAA N/A
- SPRY N/A
- EPS Growth
- STAA 9.97
- SPRY N/A
- EPS
- STAA 0.44
- SPRY N/A
- Revenue
- STAA $341,224,000.00
- SPRY $2,568,000.00
- Revenue This Year
- STAA $8.37
- SPRY $67,363.34
- Revenue Next Year
- STAA $10.55
- SPRY $511.99
- P/E Ratio
- STAA $52.79
- SPRY N/A
- Revenue Growth
- STAA 10.01
- SPRY 8460.00
- 52 Week Low
- STAA $21.13
- SPRY $6.29
- 52 Week High
- STAA $52.68
- SPRY $18.51
- Technical
- Relative Strength Index (RSI)
- STAA 44.66
- SPRY 44.57
- Support Level
- STAA $22.49
- SPRY $11.00
- Resistance Level
- STAA $24.50
- SPRY $14.87
- Average True Range (ATR)
- STAA 0.96
- SPRY 0.95
- MACD
- STAA 0.15
- SPRY 0.04
- Stochastic Oscillator
- STAA 50.24
- SPRY 31.26
About STAA STAAR Surgical Company
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of sales are generated from the ophthalmic surgical product segment.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.